CD4+ cell count at baseline was inversely related with per capita cost and this cost was particularly high in HIV+ subjects at advanced immunodeficiency stage, in agreement with previous studies [6, 19, 34–36]. This evidence concerns the gene CD4 and immunodeficiency disease.